I was just saying AMBS communicated they found a partner. They found one and the agreement is an MSA. ICON is a partner and it is logical the relationship will expand. This could just include Lympro or ICON might want a large piece or all of the Diagnostic Divison spin out. There are many ways it could happen but it will happen due to the AMBS business model. Keep in mind the diagnostic division has several assets now:

Lympro Alzheimer's
Lympro TBI/CTE
NuroPro
BC-Serapro

I believe AMBS has IP for biomarkers in many other indications that could reveal new assets in this division and don't rule out buying another diagnostic.